Will Stone

Will Stone is a KUNR alumnus, having served as a passionate, talented reporter for KUNR for nearly two years before moving in early 2015 to the major Phoenix market at public radio station KJZZ.

An East Coast transplant, he's worked at NPR stations in Philadelphia, New York and Connecticut. He's also interned at the NPR West Headquarters in Los Angeles where he learned from some of the network's best correspondents. Before joining the public radio airwaves, he studied English at a small liberal arts college and covered arts and culture for an alternative newsweekly in Philadelphia.

He's particularly drawn to education, government and environmental reporting, as listeners became aware, he jumped on any story that got him out into the field with a mic in hand.

He enjoyed the Reno outdoors, food and cultural scene, given his liking for  hiking, fish tacos and great American poetry. While KUNR listeners miss his reporting, we're always glad to help prepare, encourage and support successful public radio professionals wherever they go.

See what Will is up to at KJZZ.

When Colin Powell died this week from complications related to COVID-19, it was a shock to many Americans.

Though scientists and federal health officials are adamant that the vaccines work well to protect against hospitalization and death, it's unnerving to hear of fully vaccinated people like Powell, or perhaps your own friends and neighbors, falling severely ill with COVID-19.

So how well do the vaccines work? How serious is the risk of a serious breakthrough infection, one that could land you in the hospital?

With a second pandemic winter approaching, there are promising signs that the worst of the delta surge has run its course, but in America's hospitals — already short-staffed and backlogged from the summer torrent of COVID-19 — the relief may be only short-lived.

Many are staring down a tough stretch of colder months with the threat of a potentially bad influenza season, an influx of patients trying to catch up on delayed care and a depleted workforce that has had little time — if any — to regroup from this latest wave of coronavirus infections.

The test results that hot day in early August shouldn't have surprised me — all the symptoms were there. A few days earlier, fatigue had enveloped me like a weighted blanket. I chalked it up to my weekend of travel. Next, a headache clamped down on the back of my skull. Then my eyeballs started to ache. And soon enough, everything tasted like nothing.

The U.S. health care system is again buckling under the weight of a COVID-19 surge that has filled more than 100,000 hospital beds nationwide and forced some states to consider enacting "crisis standards of care" — a last resort plan for rationing medical care during a catastrophic event.

Booster shots against the coronavirus have already started rolling out in the U.S. for some people and millions more could be due for them soon. But as breakthrough infections become more common, many people are wondering in the meantime: Does my immune system have enough firepower to protect me right now?

With the U.S. in the grips of a frightening surge of coronavirus cases, many parents are understandably eager to know when the COVID-19 vaccine will finally be available for children under 12.

This age group accounts for about 50 million Americans and currently none of them qualify for a shot. But scientists are racing to figure out how one of the COVID-19 vaccines currently available for adults could be given to this age group.

People with compromised immune systems who already got two doses of the Pfizer or Moderna vaccines can now get a third shot to boost their protection from COVID-19.

This week's decision by federal health agencies is welcome news to many patients and their doctors who have been calling for this for months.

The Food and Drug Administration is authorizing an additional dose of a COVID-19 vaccine for certain people with weakened immune systems caused either by disease, medical treatments or organ transplants.

The move comes after studies have shown these people may not have sufficient immunity to head off the more serious complications of COVID-19 after the standard vaccine regimen.

The vast majority of COVID-19 vaccines have gone straight from drug companies to affluent countries such as the United States. Worldwide only about 1% have made it to low-income countries.

And here's what's happening all across the United States: Millions of vaccine doses at risk of spoiling are sitting on freezer shelves, with no easy way to get them to countries desperately waiting for shots.

Pages